Cutaneous reactions to chemotherapeutic agents.
The task of evaluating a cutaneous eruption in the patient receiving chemotherapy can be quite formidable. Most of the time, these patients are receiving a multitude of agents and have profound immunosuppression. These factors may alter the more common manifestations of cutaneous eruptions. This article presents some of the more common cutaneous eruptions that may occur in an oncology patient receiving chemotherapy. It is hoped we may recognize clinical patterns seen with chemotherapeutic agents in the immunosuppressed population and, by recognizing these cutaneous eruptions, we may avoid the pitfalls of discontinuing medicines that may certainly be needed or altering the treatment course in a patient.
Koppel
R A
RA
Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
Boh
E E
EE
D000505:Alopecia / Q000139:chemically induced / Q000473:pathology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology / Q000473:pathology; D004439:Eccrine Glands / Q000473:pathology; D004890:Erythema / Q000139:chemically induced / Q000473:pathology; D005499:Folliculitis / Q000139:chemically induced; D016575:Hidradenitis / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced / Q000473:pathology; D007642:Keratosis / Q000139:chemically induced; D008679:Metaplasia / Q000139:chemically induced; D009061:Mouth Mucosa / Q000187:drug effects / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D012867:Skin / Q000528:radiation effects; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology*
D000970:Antineoplastic Agents